Bioreduction of 4-nitroquinoline 1-oxide in dysplastic nevus syndrome fibroblasts.
Fibroblast strains 3012T and 3072T, derived from normal skin explants of two patients affected with familial dysplastic nevus syndrome (DNS), an hereditary variant of cutaneous malignant melanoma, have been reported to be abnormally sensitive to the cytotoxic and mutagenic effects of the procarcinogen 4-nitroquinoline 1-oxide (4NQO). In this communication we demonstrate that on exposure to a particular concentration of 4NQO, these same two DNS strains sustain an amount of DNA damage which is equal to (3012T) or only approximately 1.3 times greater than (3072T) that displayed by 8 control fibroblast strains established from clinically normal volunteers. Moreover, cell sonicates of 3072T display approximately 1.3-fold enhanced capacity to catalyze the reduction of 4NQO to the proximate carcinogen 4-hydroxyaminoquinoline 1-oxide, whereas sonicates of 3012T cells carry out this reaction at a normal rate. Accordingly, our results argue against the postulate that the 4NQO hypersensitivity exhibited by these DNS strains is merely due to an elevated capacity for bioreduction of the inert parent compound to a DNA-reactive derivative.
Mirzayans
R
R
Molecular Genetics and Carcinogenesis Laboratory, Cross Cancer Institute, Edmonton, Alberta, Canada.
Sabour
M
M
Paterson
M C
MC
D015112:4-Nitroquinoline-1-oxide / Q000378:metabolism*; D001711:Biotransformation; D002460:Cell Line; D004249:DNA Damage; D004416:Dysplastic Nevus Syndrome / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D009600:Nitroquinolines / Q000378:metabolism*; D010084:Oxidation-Reduction
D009600:Nitroquinolines; D015112:4-Nitroquinoline-1-oxide